Molecular and Cellular Mechanisms of Cancers: Urothelial Cancer

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell Microenvironment".

Deadline for manuscript submissions: closed (15 July 2024) | Viewed by 602

Special Issue Editor


E-Mail Website
Guest Editor
Division of Medical Oncology, Cardinal Massaia Hospital, Department of Oncology, University of Turin, Corso Dante Alighieri 202, 14100 Asti, Italy
Interests: kidney; urothelial
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Urothelial cancer, a prevalent malignancy affecting the urinary tract, has emerged as a critical focus of scientific inquiry within the broader context of cancer research. Urothelial cancer encompasses a group of cancers originating from the urothelial cells lining various parts of the urinary tract, including the bladder, urethra, and renal pelvis. The objective of this Special Issue is to delve into the molecular and cellular mechanisms underlying the initiation and progression of urothelial cancer, aiming to enhance our understanding of this malignancy at a deeper level.

Articles within this Special Issue will cover the pathogenic mechanisms, molecular foundations, and cellular signaling pathways associated with urothelial cancer, as well as the impact of individual variations in patients on tumor development. This Special Issue will also highlight emerging therapeutic strategies and drugs, along with their applications in clinical practice. Researchers and clinical practitioners can discover the latest scientific insights into urothelial cancer from these articles, contributing to improvements in diagnosis, treatment, and prognosis assessment.

By conducting in-depth research into the molecular and cellular mechanisms of urothelial cancer, there is potential to identify new therapeutic targets and biomarkers, providing robust support for personalized treatment and precision medicine. This Special Issue aims to offer a comprehensive and profound perspective for researchers, clinicians, and medical professionals, propelling scientific research and clinical advancements in the field of urothelial cancer.

We are pleased to invite you to contribute original articles, reviews, and communications. We look forward to your contributions to this Special Issue.

Dr. Marcello Tucci
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • urothelial cancer
  • bladder cancer
  • transitional cell carcinoma
  • molecular mechanisms
  • cellular mechanisms
  • oncogenesis
  • tumor microenvironment
  • biomarkers
  • molecular signaling
  • genetic alterations
  • epigenetics
  • immunotherapy
  • targeted therapy
  • precision medicine
  • cancer metabolism
  • apoptosis
  • tumor suppressor genes
  • oncogenes

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

15 pages, 6477 KiB  
Article
Stat3 Inhibitors TTI-101 and SH5-07 Suppress Bladder Cancer Cell Survival in 3D Tumor Models
by Surya P. Singh, Gopal Pathuri, Adam S. Asch, Chinthalapally V. Rao and Venkateshwar Madka
Cells 2024, 13(17), 1463; https://doi.org/10.3390/cells13171463 - 31 Aug 2024
Viewed by 392
Abstract
Bladder cancer (BCa) is one of the most lethal genitourinary malignancies owing to its propensity for recurrence and poor survival. The biochemical pathway, signal transducer and activator of transcription 3 (STAT3), has gained significance as a molecular pathway that promotes proliferation, invasion, and [...] Read more.
Bladder cancer (BCa) is one of the most lethal genitourinary malignancies owing to its propensity for recurrence and poor survival. The biochemical pathway, signal transducer and activator of transcription 3 (STAT3), has gained significance as a molecular pathway that promotes proliferation, invasion, and chemoresistance. In this study, we explored the targeting of STAT3 with TTI-101 and SH5-07 in BCa and elucidated the mechanisms in three-dimensional (3D) spheroid and organoid models. We optimized the growth of spheroids from human, rat, and mouse BCa cell lines (J82, NBT-II, and MB49 respectively) and organoids from BBN (N-butyl-N-(4-hydroxybutyl)-nitrosamine)-induced rat bladder tumors. Cell viability was assessed using MTT and trypan blue assays. Intracellular ATP production, ROS production, and calcium AM (CA)/EtBr staining were used to measure the spheroid and organoid inhibition and mitochondrial function. Western blot analysis was performed to evaluate the pharmacodynamic markers involved in cell proliferation, apoptosis, cancer stem cells (CSCs), and STAT3 signaling in BCa. We found that targeting STAT3 (using TTI-101 and SH5-07) significantly reduced the proliferation of BCa spheroids and organoids, which was accompanied by decreased expression of pSTAT3, Cyclin D1, and PCNA. Our data also demonstrated that treatment with STAT3 inhibitors induced ROS production and cell death in BCa spheroids and organoids. STAT3 inhibition-induced cell death was associated with the activation of caspase 3/7 and PARP cleavage. Moreover, TTI-101 and SH5-07 target cancer stem cells by downregulating the expression of CD44 and CD133 in 3D models. This study provides the first evidence for the prevention of BCa with small-molecule inhibitors TTI-101 and SH5-07 via suppression of CSCs and STAT3 signaling. Full article
(This article belongs to the Special Issue Molecular and Cellular Mechanisms of Cancers: Urothelial Cancer)
Show Figures

Figure 1

Back to TopTop